Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Jana Balcarkova"'
Autor:
Eva Kriegova, Regina Fillerova, Jiri Minarik, Jakub Savara, Jirina Manakova, Anna Petrackova, Martin Dihel, Jana Balcarkova, Petra Krhovska, Tomas Pika, Petr Gajdos, Marek Behalek, Michal Vasinek, Tomas Papajik
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
Abstract Extramedullary disease (EMM) represents a rare, aggressive and mostly resistant phenotype of multiple myeloma (MM). EMM is frequently associated with high-risk cytogenetics, but their complex genomic architecture is largely unexplored. We us
Externí odkaz:
https://doaj.org/article/37daeaba58954dc38da078cfcf51a94f
Autor:
Petra Krhovska, Tomas Pika, Jitka Proskova, Jana Balcarkova, Jana Zapletalova, Jaroslav Bacovsky, Jiri Minarik
Publikováno v:
European Journal of Haematology. 109:75-82
Our aim was to correlate serum levels of selected markers of bone metabolism and bone marrow microenvironment to cytogenetic changes in patients with multiple myeloma (MM).We assed cytogenetic changes in 308 patients and correlated them with the foll
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dadaf3dfd0b320f05b0914cdf9994d3d
https://doi.org/10.1111/ejh.13771
https://doi.org/10.1111/ejh.13771
Autor:
Patrik Flodr, Vlastimil Scudla, Jana Balcarkova, Miroslava Mlynarcikova, Jaroslav Bacovsky, Jiri Minarik, Martin Novak, Petra Krhovska, Z. Pikalová, Tomas Pika
Publikováno v:
European Journal of Haematology. 99:186-189
We present a case report of a patient relapsing after anti-CD38 treatment (daratumumab). The phenotype of the disease changed during this treatment, and the myeloma clone became CD38 negative and daratumumab refractory. We expected clonal shift, howe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::290836c26c35b66e790a808b34615d10
https://doi.org/10.1111/ejh.12902
https://doi.org/10.1111/ejh.12902
Autor:
Tereza Libigerova, Lenka Sedlarikova, Alzbeta Hamplova, Jiri Minarik, Tomas Pika, Eva Kriegova, Petra Krhovska, Anna Petrackova, Tomas Papajik, Jana Balcarkova
Publikováno v:
British journal of haematologyReferences. 189(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec2ce7dd386654e59b3a4a63e20c627e
https://pubmed.ncbi.nlm.nih.gov/32130732
https://pubmed.ncbi.nlm.nih.gov/32130732
Autor:
Tomas Papajik, Jaroslav Bacovsky, Regina Fillerova, Petr Gajdoš, Marek Behalek, Jiri Minarik, Jana Balcarkova, Petra Krhovska, Tomas Pika, Zuzana Mikulková, Jana Proskova, Anna Petrackova, Eva Kriegova
Web of Science 19 10 E64 E64
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfd18dea2b5a66739c2a7a923d732c40
http://hdl.handle.net/10084/138984
http://hdl.handle.net/10084/138984
Autor:
Patrik Flodr, Jana Balcarkova, Tomas Papajik, Nela Svobodova, Helena Urbankova, Tomas Pika, Jiri Minarik, Petra Krhovska
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e56-e57
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b126fc0c822a949c3bd519fcc2bec0da
https://doi.org/10.1016/j.clml.2019.09.087
https://doi.org/10.1016/j.clml.2019.09.087
Autor:
Ludĕk Raida, Vít Procházka, Karel Indrak, Z. Pikalová, Helena Urbankova, Milena Holzerova, Tomas Papajik, Jana Balcarkova, Marie Jarošová
Publikováno v:
Cancer Genetics and Cytogenetics. 202:58-62
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa7eb84ae73f2cdeaf39445589d347d9
https://doi.org/10.1016/j.cancergencyto.2010.06.006
https://doi.org/10.1016/j.cancergencyto.2010.06.006
Autor:
Vlastimil Scudla, Jana Balcarkova, Marie Jarošová, Jaroslav Bačovský, Milena Holzerova, Karel Indrak, Helena Urbankova
Publikováno v:
Cancer Genetics and Cytogenetics. 192:68-72
Abnormalities of chromosome 1 are among the most frequent chromosomal aberrations in patients with multiple myeloma (MM) and are considered a poor-risk genetic feature. To define the frequency and minimal region of 1q gain, we performed immunophenoty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c34efc0012b15a61e98e6fd36e2dab2
https://doi.org/10.1016/j.cancergencyto.2009.02.020
https://doi.org/10.1016/j.cancergencyto.2009.02.020
Autor:
Edgar Faber, Jana Balcarkova, Milena Holzerova, Jaroslava Voglová, Karel Chroust, Karel Indrak, Helena Urbankova, Marie Jarošová, Jan Mužík, Šárka Rožmanová, Jitka Veselovska
Publikováno v:
Cancer Genetics and Cytogenetics. 191:1-9
Reported here are 72 previously treated Philadelphia chromosome-positive (Ph+) CML patients on imatinib (IM) therapy, with a focus on patients with additional chromosomal aberrations (CAs). At the start of IM treatment, 49 patients exhibited only the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::688aa7bee62ecf1081ddb202435c9c98
https://doi.org/10.1016/j.cancergencyto.2008.12.013
https://doi.org/10.1016/j.cancergencyto.2008.12.013
Autor:
Jiri Minarik, Pavla Mickova, Jana Balcarkova, Jaroslav Bacovsky, Eva Janoušová, Vlastimil Scudla, Miroslava Mlynarcikova, Tomas Pika, Marie Jarošová
Publikováno v:
Clinical lymphoma, myelomaleukemia. 16(6)
Background The genome of multiple myeloma (MM) clonal plasma cells is characterized by genetic changes of prognostic importance. Disease progression is accompanied by a number of secondary chromosomal aberrations including chromosome 8. We focused on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a0695321bc00d77250a58abdf858270
https://pubmed.ncbi.nlm.nih.gov/27052024
https://pubmed.ncbi.nlm.nih.gov/27052024